Loader Background
Request a demo
Press release / Monday Jun 04, 2018

Quantum Surgical completes first round of financing to accelerate the development of its robotic platform for minimally invasive therapies in liver cancer

Quantum Surgical SAS, a company building next-generation solutions for minimally invasive therapies, announces the completion of its first capital increase from Ally Bridge Group (ABG), a global healthcare investment group specializing in life science companies. This Series A investment is the first tranche of a $50 million global funding from Ally Bridge Group.

Quantum Surgical is developing next-generation robotic solutions for minimally invasive cancer therapies. This platform combining robotics, image analytics, and artificial intelligence will allow more and more patients to benefit from safer interventional oncology procedures, especially in the case of early-stage liver cancers. The incidence of liver cancer in the population is, unfortunately, growing very rapidly. Liver cancer is one of the most common cancers with more than 800,000 cases each year in the world.

“Quantum will set new standards for minimally invasive cancer treatment procedures. We are excited to partner up with Ally Bridge Group – again, after our successful collaboration in 2015-2016, and to continue to benefit from ABG’s truly global industry perspectives, network and strong financing, capital markets and M&A capabilities,” said Bertin Nahum, Founder and CEO of Quantum Surgical.

“ABG is excited to support the Quantum Surgical team led by Bertin Nahum again in their entrepreneurial adventure, following our successful investment in Medtech SA. The team has a proven track record in developing and commercializing innovative surgical robots globally. ABG has been working closely with Quantum Surgical since its inception and our partnership now breaks into new ground in building next-generation surgical robots to facilitate interventional oncology treatment, especially for early stage cancer patients,” said Frank Yu, founder and president of Ally Bridge Group. “Quantum Surgical is a natural extension of ABG’s recently led US$300 million investment in GRAIL, an innovative U.S.-based company whose mission is to detect cancer early, when it can be cured. ABG has the expertise to strengthen strategic partnerships between emerging companies and industry leaders on an international level and in particular between the US, China and Europe.”

About Quantum Surgical

Co-founded in 2017 by Bertin Nahum, Quantum Surgical is an innovative Robotic Surgery start-up company based in France’s Montpellier region that is aiming is to conceive an innovative solution; a combination of powerful software and robotic platform for minimally invasive therapies in liver cancer. This platform combining robotics, image analytics, and artificial intelligence will allow more and more patients to benefit from safer interventional oncology procedures, especially in the case of early-stage liver cancers. The incidence of liver cancer in the population is, unfortunately, growing very rapidly. It is one of the most common cancers with more than 8000 new cases each year in France and 800 000 cases in the world.

Further information is available on our website: https://quantumsurgical.com/

 

About Ally Bridge Group

Ally Bridge Group (“ABG”) is a global healthcare investment group investing in some of the world’s most novel life science companies and technologies in the United States, Europe and China. ABG was founded in 2013 by Frank Yu, Chief Executive Officer and Chief Investment Officer, with dual headquarters in New York and Hong Kong. Through its scientific and clinical research overlaid with M&A and capital markets expertise, Ally Bridge Group seeks to capture investment opportunities across the capital structure addressing unmet medical needs.

For more information, please visit https://www.ally-bridge.com

Press contact